Major Estimate Revision • Apr 18
Consensus estimates of losses per share improve by 37% The consensus outlook for earnings per share (EPS) in fiscal year 2026 has improved. 2026 revenue forecast increased from ₩186.7m to ₩189.0m. EPS estimate increased from -₩786 per share to -₩496 per share. Chemicals industry in South Korea expected to see average net income growth of 62% next year. Consensus price target of ₩74,667 unchanged from last update. Share price rose 22% to ₩66,000 over the past week. Reported Earnings • Mar 13
Full year 2025 earnings: EPS and revenues miss analyst expectations Full year 2025 results: ₩5,752 loss per share (further deteriorated from ₩2,759 loss in FY 2024). Revenue: ₩133.8b (down 7.6% from FY 2024). Net loss: ₩57.8b (loss widened 111% from FY 2024). Revenue missed analyst estimates by 2.5%. Earnings per share (EPS) also missed analyst estimates significantly. Revenue is forecast to grow 40% p.a. on average during the next 2 years, compared to a 10% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 24% per year but the company’s share price has fallen by 40% per year, which means it is performing significantly worse than earnings. Annonce • Mar 07
Chunbo Co., Ltd., Annual General Meeting, Mar 24, 2026 Chunbo Co., Ltd., Annual General Meeting, Mar 24, 2026, at 10:00 Tokyo Standard Time. Location: conference room, 312, jungwonsaneop-ro, judeok-eup, chungcheongbuk-do, chungju South Korea New Risk • Mar 04
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 11% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.5x net interest cover). Earnings are forecast to decline by an average of 52% per year for the foreseeable future. Minor Risks Share price has been volatile over the past 3 months (11% average weekly change). Shareholders have been diluted in the past year (20% increase in shares outstanding). Valuation Update With 7 Day Price Move • Mar 04
Investor sentiment deteriorates as stock falls 26% After last week's 26% share price decline to ₩40,500, the stock trades at a trailing P/E ratio of 30.7x. Average forward P/E is 14x in the Chemicals industry in South Korea. Total loss to shareholders of 85% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at ₩62,042 per share. Buy Or Sell Opportunity • Mar 03
Now 26% undervalued after recent price drop Over the last 90 days, the stock has fallen 15% to ₩49,000. The fair value is estimated to be ₩66,238, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 35% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 104% in 2 years. Earnings are forecast to decline by 132% in the next 2 years. Buy Or Sell Opportunity • Feb 13
Now 21% undervalued after recent price drop Over the last 90 days, the stock has fallen 22% to ₩51,100. The fair value is estimated to be ₩64,568, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has declined by 35% over the last 3 years. Meanwhile, the company has become profitable. Revenue is forecast to grow by 104% in 2 years. Earnings are forecast to decline by 132% in the next 2 years. Valuation Update With 7 Day Price Move • Jan 28
Investor sentiment improves as stock rises 25% After last week's 25% share price gain to ₩61,000, the stock trades at a trailing P/E ratio of 45.3x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total loss to shareholders of 75% over the past three years. Price Target Changed • Jan 16
Price target increased by 13% to ₩68,833 Up from ₩60,857, the current price target is an average from 6 analysts. New target price is 44% above last closing price of ₩47,700. Stock is up 23% over the past year. The company is forecast to post a net loss per share of ₩636 next year compared to a net loss per share of ₩2,759 last year. New Risk • Jan 09
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 17% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.5x net interest cover). Share price has been highly volatile over the past 3 months (12% average weekly change). Earnings are forecast to decline by an average of 102% per year for the foreseeable future. Minor Risk Shareholders have been diluted in the past year (17% increase in shares outstanding). Valuation Update With 7 Day Price Move • Dec 09
Investor sentiment improves as stock rises 16% After last week's 16% share price gain to ₩68,000, the stock trades at a trailing P/E ratio of 43.2x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total loss to shareholders of 71% over the past three years. Valuation Update With 7 Day Price Move • Nov 19
Investor sentiment deteriorates as stock falls 17% After last week's 17% share price decline to ₩55,300, the stock trades at a trailing P/E ratio of 39.6x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total loss to shareholders of 76% over the past three years. Major Estimate Revision • Nov 18
Consensus revenue estimates fall by 11% The consensus outlook for revenues in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from ₩153.1m to ₩135.9m. Forecast losses increased from -₩346 to -₩636 per share. Chemicals industry in South Korea expected to see average net income growth of 52% next year. Consensus price target up from ₩59,143 to ₩63,000. Share price fell 15% to ₩57,000 over the past week. Valuation Update With 7 Day Price Move • Oct 17
Investor sentiment improves as stock rises 40% After last week's 40% share price gain to ₩59,600, the stock trades at a trailing P/E ratio of 42.7x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total loss to shareholders of 72% over the past three years. New Risk • Oct 16
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.5x net interest cover). Earnings are forecast to decline by an average of 116% per year for the foreseeable future. Minor Risk Share price has been volatile over the past 3 months (7.7% average weekly change). New Risk • Aug 22
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 7.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.4x net interest cover). Earnings are forecast to decline by an average of 35% per year for the foreseeable future. Minor Risk Share price has been volatile over the past 3 months (7.8% average weekly change). Major Estimate Revision • Aug 20
Consensus revenue estimates decrease by 12%, EPS upgraded The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from ₩173.8m to ₩153.1m. EPS estimate increased from -₩736 to -₩678 per share. Chemicals industry in South Korea expected to see average net income growth of 35% next year. Consensus price target broadly unchanged at ₩59,143. Share price fell 8.9% to ₩44,600 over the past week. New Risk • May 23
New major risk - Revenue and earnings growth Earnings are forecast to decline by an average of 22% per year for the foreseeable future. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are expected to decline, then in most cases the share price will decline over time as well. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (0.4x net interest cover). Earnings are forecast to decline by an average of 22% per year for the foreseeable future. Major Estimate Revision • May 16
Consensus EPS estimates fall by 205% The consensus outlook for fiscal year 2025 has been updated. 2025 expected loss increased from -₩259 to -₩790 per share. Revenue forecast unchanged at ₩175.4m. Chemicals industry in South Korea expected to see average net income growth of 34% next year. Consensus price target broadly unchanged at ₩55,125. Share price rose 2.9% to ₩34,950 over the past week. Major Estimate Revision • May 02
Consensus EPS estimates fall by 545%, revenue upgraded The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast increased from ₩174.3m to ₩176.8m. Forecast EPS reduced from -₩40.19 to -₩259 per share. Chemicals industry in South Korea expected to see average net income growth of 35% next year. Consensus price target down from ₩57,875 to ₩55,375. Share price fell 3.8% to ₩35,750 over the past week. Price Target Changed • May 01
Price target decreased by 9.4% to ₩55,375 Down from ₩61,125, the current price target is an average from 8 analysts. New target price is 53% above last closing price of ₩36,200. Stock is down 53% over the past year. The company is forecast to post a net loss per share of ₩259 next year compared to a net loss per share of ₩2,759 last year. Major Estimate Revision • Apr 09
Consensus revenue estimates decrease by 16% The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from ₩207.8m to ₩174.3m. EPS estimate unchanged from -₩40.19 per share at last update. Chemicals industry in South Korea expected to see average net income growth of 31% next year. Consensus price target down from ₩65,375 to ₩63,857. Share price fell 7.3% to ₩30,300 over the past week. Major Estimate Revision • Apr 03
Consensus EPS estimates fall by 64% The consensus outlook for earnings per share (EPS) in fiscal year 2025 has deteriorated. 2025 revenue forecast decreased from ₩207.8m to ₩189.6m. Losses expected to increase from ₩389 per share to ₩640. Chemicals industry in South Korea expected to see average net income growth of 31% next year. Consensus price target down from ₩65,375 to ₩61,125. Share price fell 11% to ₩31,500 over the past week. Major Estimate Revision • Mar 21
Consensus EPS estimates upgraded to ₩389 loss, revenue downgraded The consensus outlook for fiscal year 2025 has been updated. 2025 revenue forecast fell from ₩229.2m to ₩207.8m. 2025 losses expected to reduce from -₩542 to -₩389 per share. Chemicals industry in South Korea expected to see average net income growth of 28% next year. Consensus price target broadly unchanged at ₩66,444. Share price rose 3.1% to ₩37,800 over the past week. Reported Earnings • Mar 13
Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind Full year 2024 results: ₩2,759 loss per share (improved from ₩4,205 loss in FY 2023). Revenue: ₩144.9b (down 21% from FY 2023). Net loss: ₩27.4b (loss narrowed 34% from FY 2023). Revenue missed analyst estimates by 6.6%. Earnings per share (EPS) exceeded analyst estimates by 46%. Revenue is forecast to grow 47% p.a. on average during the next 2 years, compared to a 11% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 50 percentage points per year, which is a significant difference in performance. Annonce • Mar 06
Chunbo Co., Ltd., Annual General Meeting, Mar 20, 2025 Chunbo Co., Ltd., Annual General Meeting, Mar 20, 2025, at 10:00 Tokyo Standard Time. Location: conference room, 312, jungwonsaneop-ro, judeok-eup, chungcheongbuk-do, chungju South Korea Annonce • Nov 30
Chunbo Co., Ltd. announced that it has received KRW 200 billion in funding from a group of investors On November 29, 2024 Chunbo Co., Ltd. closed the transaction. Major Estimate Revision • Nov 16
Consensus EPS estimates upgraded to ₩5,074 loss, revenue downgraded The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from ₩173.9m to ₩157.3m. 2024 losses expected to reduce from -₩5,968 to -₩5,074 per share. Chemicals industry in South Korea expected to see average net income growth of 35% next year. Consensus price target down from ₩78,222 to ₩69,667. Share price fell 26% to ₩36,900 over the past week. Major Estimate Revision • Oct 15
Consensus EPS estimates fall by 75% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from ₩177.7m to ₩173.9m. Losses expected to increase from ₩3,404 per share to ₩5,968. Chemicals industry in South Korea expected to see average net income growth of 55% next year. Consensus price target down from ₩80,778 to ₩78,222. Share price fell 9.3% to ₩58,500 over the past week. Major Estimate Revision • Sep 05
Consensus EPS estimates fall by 13% The consensus outlook for earnings per share (EPS) in fiscal year 2024 has deteriorated. 2024 revenue forecast decreased from ₩181.7m to ₩175.9m. Losses expected to increase from ₩3,151 per share to ₩3,556. Chemicals industry in South Korea expected to see average net income growth of 63% next year. Consensus price target down from ₩83,000 to ₩80,778. Share price was steady at ₩58,700 over the past week. Reported Earnings • Aug 16
Second quarter 2024 earnings released: ₩2,196 loss per share (vs ₩3,107 loss in 2Q 2023) Second quarter 2024 results: ₩2,196 loss per share (improved from ₩3,107 loss in 2Q 2023). Revenue: ₩35.9b (down 24% from 2Q 2023). Net loss: ₩21.8b (loss narrowed 29% from 2Q 2023). Revenue is forecast to grow 35% p.a. on average during the next 3 years, compared to a 15% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 58 percentage points per year, which is a significant difference in performance. Price Target Changed • Jun 21
Price target decreased by 18% to ₩98,800 Down from ₩119,917, the current price target is an average from 10 analysts. New target price is 36% above last closing price of ₩72,700. Stock is down 63% over the past year. The company is forecast to post a net loss per share of ₩3,408 next year compared to a net loss per share of ₩4,205 last year. Major Estimate Revision • May 30
Consensus revenue estimates decrease by 11% The consensus outlook for fiscal year 2024 has been updated. 2024 revenue forecast fell from ₩228.0m to ₩204.0m. EPS estimate unchanged from -₩3,544 per share at last update. Chemicals industry in South Korea expected to see average net income growth of 78% next year. Consensus price target down from ₩129,083 to ₩119,917. Share price fell 5.5% to ₩71,700 over the past week. Price Target Changed • May 25
Price target decreased by 7.9% to ₩123,250 Down from ₩133,833, the current price target is an average from 12 analysts. New target price is 70% above last closing price of ₩72,700. Stock is down 61% over the past year. The company is forecast to post a net loss per share of ₩2,724 next year compared to a net loss per share of ₩4,205 last year. Reported Earnings • Mar 15
Full year 2023 earnings released: ₩4,205 loss per share (vs ₩3,763 profit in FY 2022) Full year 2023 results: ₩4,205 loss per share (down from ₩3,763 profit in FY 2022). Revenue: ₩182.7b (down 44% from FY 2022). Net loss: ₩41.8b (down 212% from profit in FY 2022). Revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Chemicals industry in South Korea. Over the last 3 years on average, earnings per share has fallen by 57% per year but the company’s share price has only fallen by 19% per year, which means it has not declined as severely as earnings. New Risk • Mar 15
New major risk - Revenue and earnings growth Earnings have declined by 6.0% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (1.7x net interest cover). Earnings have declined by 6.0% per year over the past 5 years. Price Target Changed • Feb 22
Price target decreased by 8.6% to ₩143,538 Down from ₩157,077, the current price target is an average from 13 analysts. New target price is 47% above last closing price of ₩97,700. Stock is down 58% over the past year. The company is forecast to post a net loss per share of ₩2,706 compared to earnings per share of ₩3,763 last year. Upcoming Dividend • Dec 20
Upcoming dividend of ₩500 per share at 0.4% yield Eligible shareholders must have bought the stock before 27 December 2023. Payment date: 10 April 2024. The company is not currently making a profit and is not cash flow positive. Trailing yield: 0.4%. Lower than top quartile of South Korean dividend payers (3.5%). Lower than average of industry peers (1.8%). Price Target Changed • Nov 14
Price target decreased by 8.4% to ₩199,083 Down from ₩217,333, the current price target is an average from 12 analysts. New target price is 102% above last closing price of ₩98,500. Stock is down 62% over the past year. The company is forecast to post a net loss per share of ₩910 compared to earnings per share of ₩3,763 last year. New Risk • Nov 06
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of South Korean stocks, typically moving 9.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risk Debt is not well covered by operating cash flow (16% operating cash flow to total debt). Minor Risk Share price has been volatile over the past 3 months (9.0% average weekly change). Price Target Changed • Oct 24
Price target decreased by 13% to ₩224,833 Down from ₩258,583, the current price target is an average from 12 analysts. New target price is 102% above last closing price of ₩111,400. Stock is down 48% over the past year. The company is forecast to post earnings per share of ₩829 for next year compared to ₩3,763 last year. Price Target Changed • Sep 02
Price target decreased by 7.5% to ₩275,250 Down from ₩297,545, the current price target is an average from 12 analysts. New target price is 85% above last closing price of ₩148,700. Stock is down 32% over the past year. The company is forecast to post earnings per share of ₩2,592 for next year compared to ₩3,763 last year. Major Estimate Revision • Aug 17
Consensus revenue estimates fall by 10% The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from ₩299.0m to ₩267.7m. EPS estimate fell from ₩2,562 to ₩1,832 per share. Net income forecast to grow 17% next year vs 17% growth forecast for Chemicals industry in South Korea. Consensus price target down from ₩297,545 to ₩285,727. Share price fell 15% to ₩147,900 over the past week. Valuation Update With 7 Day Price Move • Aug 16
Investor sentiment deteriorates as stock falls 19% After last week's 19% share price decline to ₩138,500, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 13x in the Chemicals industry in South Korea. Total returns to shareholders of 11% over the past three years. Major Estimate Revision • Jul 22
Consensus EPS estimates fall by 16% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from ₩320.4m to ₩312.6m. EPS estimate also fell from ₩3,330 per share to ₩2,810 per share. Net income forecast to grow 51% next year vs 38% growth forecast for Chemicals industry in South Korea. Consensus price target of ₩297,545 unchanged from last update. Share price rose 6.1% to ₩198,000 over the past week. Major Estimate Revision • May 02
Consensus revenue estimates decrease by 27% The consensus outlook for fiscal year 2023 has been updated. 2023 revenue forecast fell from ₩432.8m to ₩317.6m. EPS estimate unchanged from ₩3,578 per share at last update. Chemicals industry in South Korea expected to see average net income growth of 23% next year. Consensus price target down from ₩326,636 to ₩317,545. Share price was steady at ₩193,700 over the past week. Valuation Update With 7 Day Price Move • Apr 25
Investor sentiment deteriorates as stock falls 23% After last week's 23% share price decline to ₩195,000, the stock trades at a forward P/E ratio of 33x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 200% over the past three years. Major Estimate Revision • Apr 13
Consensus EPS estimates increase by 11% The consensus outlook for earnings per share (EPS) in fiscal year 2023 has improved. 2023 revenue forecast increased from ₩407.0m to ₩432.8m. EPS estimate increased from ₩5,389 to ₩5,970 per share. Net income forecast to grow 65% next year vs 33% growth forecast for Chemicals industry in South Korea. Consensus price target up from ₩315,300 to ₩326,636. Share price rose 3.0% to ₩261,000 over the past week. Major Estimate Revision • Mar 15
Consensus revenue estimates fall by 20% The consensus outlook for revenues in fiscal year 2023 has deteriorated. 2023 revenue forecast decreased from ₩507.9m to ₩407.5m. EPS estimate fell from ₩7,701 to ₩4,928 per share. Net income forecast to grow 39% next year vs 30% growth forecast for Chemicals industry in South Korea. Consensus price target broadly unchanged at ₩315,300. Share price fell 14% to ₩226,500 over the past week. Upcoming Dividend • Dec 21
Upcoming dividend of ₩500 per share Eligible shareholders must have bought the stock before 28 December 2022. Payment date: 10 April 2023. Payout ratio is a comfortable 5.3% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of South Korean dividend payers (3.3%). Lower than average of industry peers (2.4%). Price Target Changed • Sep 09
Price target decreased to ₩360,000 Down from ₩396,667, the current price target is an average from 9 analysts. New target price is 62% above last closing price of ₩222,900. Stock is down 16% over the past year. The company is forecast to post earnings per share of ₩4,791 for next year compared to ₩4,438 last year. Valuation Update With 7 Day Price Move • May 19
Investor sentiment improved over the past week After last week's 15% share price gain to ₩283,200, the stock trades at a forward P/E ratio of 50x. Average forward P/E is 12x in the Chemicals industry in South Korea. Total returns to shareholders of 283% over the past three years. Reported Earnings • Mar 19
Full year 2021 earnings: Revenues exceed analysts expectations while EPS lags behind Full year 2021 results: EPS: ₩4,438 (up from ₩2,767 in FY 2020). Revenue: ₩271.6b (up 75% from FY 2020). Net income: ₩43.8b (up 60% from FY 2020). Profit margin: 16% (down from 18% in FY 2020). The decrease in margin was driven by higher expenses. Revenue exceeded analyst estimates by 2.5%. Earnings per share (EPS) missed analyst estimates by 100%. Over the next year, revenue is forecast to grow 45%, compared to a 19% growth forecast for the industry in South Korea. Over the last 3 years on average, earnings per share has increased by 13% per year but the company’s share price has increased by 60% per year, which means it is tracking significantly ahead of earnings growth. Valuation Update With 7 Day Price Move • Jan 27
Investor sentiment deteriorated over the past week After last week's 16% share price decline to ₩262,500, the stock trades at a forward P/E ratio of 44x. Average forward P/E is 10x in the Chemicals industry in South Korea. Total returns to shareholders of 42% over the past year. Upcoming Dividend • Dec 22
Upcoming dividend of ₩300 per share Eligible shareholders must have bought the stock before 29 December 2021. Payment date: 11 April 2022. Payout ratio is a comfortable 7.5% but the company is not cash flow positive. Trailing yield: 0.1%. Lower than top quartile of South Korean dividend payers (2.4%). Lower than average of industry peers (1.4%). Valuation Update With 7 Day Price Move • Sep 08
Investor sentiment improved over the past week After last week's 15% share price gain to ₩265,500, the stock trades at a forward P/E ratio of 51x. Average forward P/E is 13x in the Chemicals industry in South Korea. Total returns to shareholders of 72% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₩137,141 per share. Price Target Changed • Aug 22
Price target increased to ₩296,429 Up from ₩270,714, the current price target is an average from 7 analysts. New target price is 24% above last closing price of ₩238,900. Stock is up 63% over the past year. Price Target Changed • Jul 20
Price target increased to ₩266,429 Up from ₩243,889, the current price target is an average from 7 analysts. New target price is 19% above last closing price of ₩223,100. Stock is up 137% over the past year. Valuation Update With 7 Day Price Move • Jul 09
Investor sentiment improved over the past week After last week's 20% share price gain to ₩217,500, the stock trades at a forward P/E ratio of 47x. Average forward P/E is 11x in the Chemicals industry in South Korea. Total returns to shareholders of 119% over the past year. Simply Wall St's valuation model estimates the intrinsic value at ₩279,646 per share. Price Target Changed • Jul 08
Price target increased to ₩260,714 Up from ₩237,222, the current price target is an average from 8 analysts. New target price is 27% above last closing price of ₩205,500. Stock is up 106% over the past year. Reported Earnings • Mar 11
Full year 2020 earnings released: EPS ₩2,742 (vs ₩2,348 in FY 2019) The company reported a solid full year result with improved earnings and revenues, although profit margins were flat. Full year 2020 results: Revenue: ₩155.5b (up 15% from FY 2019). Net income: ₩27.3b (up 19% from FY 2019). Profit margin: 18% (in line with FY 2019). Is New 90 Day High Low • Feb 26
New 90-day low: ₩160,200 The company is down 11% from its price of ₩180,300 on 27 November 2020. The South Korean market is up 16% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 13% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩139,545 per share. Price Target Changed • Jan 07
Price target raised to ₩204,250 Up from ₩184,400, the current price target is an average from 8 analysts. The new target price is 8.1% above the current share price of ₩189,000. As of last close, the stock is up 194% over the past year. Is New 90 Day High Low • Jan 04
New 90-day high: ₩191,700 The company is up 13% from its price of ₩169,100 on 06 October 2020. The South Korean market is up 21% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Chemicals industry, which is up 22% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is ₩139,908 per share. Price Target Changed • Dec 15
Price target raised to ₩184,400 Up from ₩154,333, the current price target is an average from 11 analysts. The new target price is 7.8% above the current share price of ₩171,000. As of last close, the stock is up 215% over the past year. Valuation Update With 7 Day Price Move • Nov 03
Market bids up stock over the past week After last week's 18% share price gain to ₩164,400, the stock is trading at a trailing P/E ratio of 74.6x, up from the previous P/E ratio of 63.2x. This compares to an average P/E of 12x in the Chemicals industry in South Korea. Total returns to shareholders over the past year are 155%.